Clinical Trial Update: Biomarker Assessments of Leukine During Treatment of Parkinson's Disease [Phase 1]

View source ↗

Summary

This is a Phase 1 trial evaluating biomarker responses to Leukine (sargramostim) during treatment of Parkinson disease. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: University of Nebraska | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED